2O12,1QXO,1Q1L,1UM0,1SQ1,1R53


Conserved Protein Domain Family
Chorismate_synthase

?
cd07304: Chorismate_synthase 
Click on image for an interactive view with Cn3D
Chorismase synthase, the enzyme catalyzing the final step of the shikimate pathway.
Chorismate synthase (CS; 5-enolpyruvylshikimate-3-phosphate phospholyase; 1-carboxyvinyl-3-phosphoshikimate phosphate-lyase; E.C. 4.2.3.5) catalyzes the seventh and final step in the shikimate pathway: the conversion of 5- enolpyruvylshikimate-3-phosphate (EPSP) to chorismate, a precursor for the biosynthesis of aromatic compounds. This process has an absolute requirement for reduced FMN as a co-factor which is thought to facilitate cleavage of C-O bonds by transiently donating an electron to the substrate, having no overall change its redox state. Depending on the capacity of these enzymes to regenerate the reduced form of FMN, chorismate synthases are divided into two classes: Enzymes, mostly from plants and eubacteria, that sequester CS from the cellular environment, are monofunctiona,l while those that can generate reduced FMN at the expense of NADPH, such as found in fungi and the ciliated protozoan Euglena gracilis, are bifunctional, having an additional NADPH:FMN oxidoreductase activity. Recently, bifunctionality of the Mycobacterium tuberculosis enzyme (MtCS) was determined by measurements of both chorismate synthase and NADH:FMN oxidoreductase activities. Since shikimate pathway enzymes are present in bacteria, fungi and apicomplexan parasites (such as Toxoplasma gondii, Plasmodium falciparum, and Cryptosporidium parvum) but absent in mammals, they are potentially attractive targets for the development of new therapy against infectious diseases such as tuberculosis (TB).
Statistics
?
PSSM-Id: 143612
View PSSM: cd07304
Aligned: 143 rows
Threshold Bit Score: 345.172
Threshold Setting Gi: 229849049
Created: 30-Sep-2008
Updated: 17-Jan-2013
Structure
?
Program:
Drawing:
Aligned Rows:
 
Conserved site includes 15 residues -Click on image for an interactive view with Cn3D
Feature 1:FMN-binding site [chemical binding site]
Evidence:

Sequence Alignment
?
Format: Row Display: Color Bits: Type Selection:
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                                                                        
2O12_A         2 LRWITAGESHGRALVAVVEGMVAGVHVTSADIADQLARRRLGyGRGARMTFERDAVTVlSGIRHGSTLGGPIAIEIGNTE 81
gi 166218017   1 MRFLDAGETHGRCLVGIIEGFPANVKINIDNINRLLELRQRGyGRGKRMEIEKDKATIlSGVRNSYTTGAPITIMIENRD 80
gi 164686406   4 LRYLTSGESHGQSLISIIDGLPSNVELNFDEINAELKKRQCGyGRGGRMKIESDKVNIlGGVRGKKTLGGPVSIEVKNRD 83
gi 189485285   2 IRFTTAGESHGEGLFVIIEGIPAGLTINSEDIDLELARRQKGyGRGQRMCIETDTVKVfSGMRHTVSLGSPIAMYIANKD 81
gi 81848112    1 MRYLTAGESHGEALIAIIEGLPSNLFIDAEFINKELERRQKGyGRGGRMAIEKDEIHIiSGVRDGKTTGAPLAMEIKNRD 80
gi 122482467   1 MRYLTAGESHGPKLVGILEGVPSGAKIDKETIDQALQERQKGpGRGGRMKIEKDQVTIlSGVRGGLTTGAPIALEIINRD 80
gi 58651777    5 LRYYSAGESHGRGIFAFLDGFPAGVRVQPDDINFWLAERQKGyGRGGRQRIEKDEVDVlSGIRGGVTLGSPILLAVWNRD 84
gi 87309292    2 LRYSTAGESHGKTLLALVDGFPAGVEIETDAIDADLKLRQGGyGRGGRQRIETDKVEVlTGIWKGLSLGSPIALQVVNKD 81
gi 28211721    7 LRFLDAGESHGKAMMSIIDGIPSNFKVDIDFINNELKRRQKCyGRGGRMKIEKDKIQFlSGLRGTMTTGNPITMAIYNND 86
gi 12229726    1 MKLTIAGDSHGKYMVAILEGLPSGIRVDEELIRRDLFRRRNCyGRGKRMKMEEDAFEIvSGLWKGITTGAPVTILIPNRA 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                        ###                  # #                        
2O12_A        82 WPKWETvmaadpvdpaeladvarnaplTRPRPGHADYAGMLKYGfdDARPVLERASARETAARVAAGTVARAFLRqalgV 161
gi 166218017  81 YVNWQKymdpilc-------dtmtkkvTVPRPGHADLPGCLKYGfdDARPVLERASARETAMRVAIGALCEELLNvf-gI 152
gi 164686406  84 YQNWTEymapmddv------dfetrkvDNVRPGHADLVGCLKYDftDARNVLERSSARETASRVAVGAICKQVLKnf-dI 156
gi 189485285  82 FKNWTKimsptsv-------dsevtplLRPRPGHADLPGFMKYGvnDFRDILERASARETAARVAAGAVCKALLKef-eI 153
gi 81848112   81 YKNWKDkkv---------------ppvTRPRPGHADLPGSIKYNqrDIRNILERASARETAARVAVGSVAKLLLKel-nI 144
gi 122482467  81 WANWEKimawgdea------dlesrkvITPRPGHADLTGHLKYRt-EVRNVLERASARETAMRVAIGNIAVQILEal-gV 152
gi 58651777   85 FKNWESamdpwkps-----tgerarkvVRPRPSHADLVGALKYEhdDCRNILERASARETAARVAAGALCRKLLAef-gV 158
gi 87309292   82 YKLERLed------------------lPRPRPGHGDLTGAIKYLg-PVRGILERASARETAVRVAAGGLAKLLLKqf-gI 141
gi 28211721   87 SPNWEKilsgev---------kkdekiTIPRPGHGDLVGYFKYGtgDIRDSIERTSARETSIRTAVGALCKQILKgi-gI 156
gi 12229726   81 GNPVKDv-------------------rSVPRPGHIDYAAWVKYKlpDLNIYVERSSARWTVALTAAGSLLKSLLKef-gI 140
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                                                                        
2O12_A       162 EVLSHVISIGasapyegppprae-dlpaidaspvrayDKAAEADMIAQIEAAKKDGDTLGGVVEAVAlGLPVGLGSFTSg 240
gi 166218017 153 KLYNHVVEIGgvrikkeystddvnlfeeaensdlfciDKEAENDMKQVIDSAKEAGDSVGGVAEVICkNVPFGLGSHVHw 232
gi 164686406 157 DFVSHVIQIGnvkdenvydfdyi--knnvdssevrcaNKDMEAKMISQIDEIKNERDTIGGVVEVRVkNLIPGLGSYTQf 234
gi 189485285 154 SIVSYTSQIGdvtadissveeck-iwhdaeiscvrcpDAKASEKMIQLIKKAGEKGDTLGGKVVVVTkNVPAGLGSHTQw 232
gi 81848112  145 SLKSRVLEIG---------------------------GAKREEKWKRLIEKAKKEGDTLGGIIEIVIeGVPVGLGSHAQw 197
gi 122482467 153 EIRGQVLSVGkvhmnsedtpey---wqrvqasewkvgDPQGEEALYTQLQEARSKGESLGGVLQIQVqNLLPGLGSYVQw 229
gi 58651777  159 DMVGHVVQIGeaaadtdriptae-lrersmasdvrcaDAEAGTRMREAIRQAKRDKDSLGGIIEVRAwGLPAGLGSHTQa 237
gi 87309292  142 TAFGYVAELGgvqitpqagdlek-lrklrsdsivyslNPDQDAEIKQLIDATGKSGDTLGGIVEVRVdGVPFGLGTHSQw 220
gi 28211721  157 EVRSKVYSIGnlfdekvdlfdqc-kykkidnsllrcyNEEVEKSFVKKIDICREQGETIGGTVFLSVrGVPIGLGSYSQw 235
gi 12229726  141 EVLGFVTRLGnveardipgdfee-lkrrrdesvvfcpDPEATKEMVAEIDRAKEEGNTLGGKVKVIArGVPAGIGSYSDl 219
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                      ###                                                               
2O12_A       241 dHRLDSQLAAAVMGIQAIKGVEIGd-----GFQTArrrGSRAHDEmypgpd-------gvvrsTNRAGGLEGGMTNGQPL 308
gi 166218017 233 dRKLDGLLAQAVMSIQSVKGVEIGm-----GFEVSrrfGSEVHDEifyddq------kgfyrkTNNAGGIEGGISNGMDI 301
gi 164686406 235 dRKIDGVMAMHLMGIQAIKGVEFGi-----GFDVAklpGSKVMDEivynqe------agikrvTNRLGGIEGGMTTGEEL 303
gi 189485285 233 dLKLDGRLAQSLISIQAVKAVEFGa-----GTKLAsllGALSHDEifydvt------rgfyrdTNRAGGIEGGMSNGEPI 301
gi 81848112  198 dRKLDALLAYHVMSVQGIKGVEFGl-----GFEAArlpGSLVHDDiyyken------egfyrkTNNAGGIEGGMSNGNPI 266
gi 122482467 230 dRKLDGRLAQAVLSVQAIKGVAFGm-----GFAAGqhfGSEVHDPigydsg------rgyyrySNNAGGIEGGMTNGEPV 298
gi 58651777  238 dRKLDAAIAQAMMSIQAVKGVEVGi-----GFRGAhlrGSAYHDEivwseapk--ggshyvrtSNHLGGTEGGMSSGEEL 310
gi 87309292  221 dRKLDGRLAQAVMAVQAIKGVEIGl-----GFEAArrpGSQVHDPihfdpehrdqphlgfvrpTNNAGGLEAGMTNGQPV 295
gi 28211721  236 dRKLDALLSYAIMSLQGVKAIEFGn-----GMNLNl-rGSTFNDEilyekg-------kfkrpTNNCGGIESGVSNGENI 302
gi 12229726  220 fKKLDSKIGSLFFAIPAVKGVVIGseemwyGFDYLd--EFELEDGkik-------------rkTNNLGGIEGGITNGEDV 284
                        330       340       350       360       370
                 ....*....|....*....|....*....|....*....|....*....|....*..
Feature 1              # ###                       #  #  #                
2O12_A       309 RVRAAMKPISTVPRalatvdlatgdeaVAIHQRSDVCAVPAAGVVVETMVALVLARA 365
gi 166218017 302 VIRAAFKPIPTLYKplrsvdlqglkekEAAVERSDTCAVPAGSVVMRAAVAYVLANS 358
gi 164686406 304 VVRCAMKPIPTLYKplnsinvntlekyEATVERSDTCAVPACSVVCENVVAFVICQF 360
gi 189485285 302 VVTCTMKAIPSLANplhsvnlatketaEAEAIRSDVCAVPAVGIVAEAAIAVELAKA 358
gi 81848112  267 VIRAAMKPIPTLLRpldsvdiatkeetKAIYERSDVTAVEAAACVLEAVCAWVIADE 323
gi 122482467 299 IIEAVMKPIPTLYSplstvnletkevmEASVERSDVCAVPAALVVLKHVAAWEILQA 355
gi 58651777  311 LVRIVKKPISTLMRplrtvnietrqpdAALVERSDTCAVPALALIAEHAVAIVLAQF 367
gi 87309292  296 IIRAAKKPISTLAKpldsinldtkekqGASYERSDVCAVSAAAIIVENVVAFEIATA 352
gi 28211721  303 EMKVYIKPIPSIKKnirtvnlrnrketTTRYERSDVSAVVPASIVLENIVAFEILKE 359
gi 12229726  285 WVNVSVKPIPTTGKplksvdlrtmepaKTPYVRSDVTAVPPASVVCEAALAVVISDA 341

| Disclaimer | Privacy statement | Accessibility |
NCBI Home NCBI Search NCBI SiteMap